Ex-Div Reminder for First Defiance Financial (FDEF)

Looking at the universe of stocks we cover at Dividend Channel, on 5/19/15, First Defiance Financial Corp. (FDEF) will trade ex-dividend, for its quarterly dividend of $0.20, payable on 5/28/15. As a percentage of FDEF's recent stock price of $36.93, this dividend works out to approximately 0.54%, so look for shares of First Defiance Financial Corp. to trade 0.54% lower — all else being equal — when FDEF shares open for trading on 5/19/15.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for FDEF, showing historical dividends prior to the most recent $0.20 declared by First Defiance Financial Corp.:

FDEF+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from FDEF is likely to continue, and whether the current estimated yield of 2.17% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of FDEF shares, versus its 200 day moving average:

First Defiance Financial Corp. 200 Day Moving Average Chart

Looking at the chart above, FDEF's low point in its 52 week range is $26.75 per share, with $37.97 as the 52 week high point — that compares with a last trade of $36.93.

In Friday trading, First Defiance Financial Corp. shares are currently up about 0.4% on the day.

More from Stocks

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Stocks Are Lower as Dow Heads for Eighth Straight Drop

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Why Spotify Is the Ultimate Speculative Stock to Buy

Why Spotify Is the Ultimate Speculative Stock to Buy

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data